http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Nakao, Makoto,Hosono, Satoyo,Ito, Hidemi,Oze, Isao,Watanabe, Miki,Mizuno, Nobumasa,Yatabe, Yasushi,Yamao, Kenji,Niimi, Akio,Tajima, Kazuo,Tanaka, Hideo,Matsuo, Keitaro Asian Pacific Journal of Cancer Prevention 2013 Asian Pacific journal of cancer prevention Vol.14 No.7
Background: Cigarette smoking is a well-established risk factor of pancreatic cancer (PC). Although an association between nicotine dependence phenotype, namely time to first cigarette (TTFC) after waking, and the risk of several smoking-related cancers has been reported, an association between TTFC and PC risk has not been reported. We assessed the impact of smoking behavior, particularly TTFC, on PC risk in a Japanese population. Materials and Methods: We conducted a case-control study using 341 PC and 1,705 non-cancer patients who visited Aichi Cancer Center in Nagoya, Japan. Exposure to risk factors, including smoking behavior, was assessed from the results of a self-administered questionnaire. The impact of smoking on PC risk was assessed with multivariate logistic regression analysis adjusted for potential confounders to estimate odds ratios (ORs) and 95% confidence intervals (CIs). Results: Cigarettes per day (CPD) and/or smoking duration were significantly associated with PC risk, consistent with previous studies. For TTFC and PC risk, we found only a suggestive association: compared with a TTFC of more than 60 minutes, ORs were 1.15 (95%CI, 0.65-2.04) for a TTFC of 30-60 minutes and 1.35 (95%CI, 0.85-2.15) for that of 0-30 minutes (p trend=0.139). After adjustment for CPD or smoking duration, no association was observed between TTFC and PC. Conclusions: In this study, we found no statistically significant association between TTFC and PC risk. Further studies concerning TTFC and PC risk are warranted.
Cr(VI) Formation Related to Cr(III)-Muscovite and Birnessite Interactions in Ultramafic Environments
Rajapaksha, Anushka Upamali,Vithanage, Meththika,Ok, Yong Sik,Oze, Christopher American Chemical Society 2013 Environmental science & technology Vol.47 No.17
<P>Chromium is abundantly and primarily present as Cr(III) in ultramafic rocks and serpentine soils. Chromium(III) oxidation involving chromite (FeCr<SUB>2</SUB>O<SUB>4</SUB>) via interactions with birnessite has been shown to be a major pathway of Cr(VI) production in serpentine soils. Alternatively, Cr(III)-bearing silicates with less Cr(III) may provide higher Cr(VI) production rates compared to relatively insoluble chromite. Of the potential Cr(III)-bearing silicates, Cr(III)-muscovite (i.e., fuchsite) commonly occurs in metamorphosed ultramafic rocks and dissolution rates may be comparable to other common Cr(III)-bearing phyllosilicates and clays. Here, we examine the formation of Cr(VI) related to Cr(III)-muscovite and birnessite (i.e., acid birnessite) interactions with and without humic matter (HM) via batch experiments. Experimentally, the fastest rate of Cr(VI) production involving Cr(III)-muscovite was 3.8 × 10<SUP>–1</SUP> μM h<SUP>–1</SUP> (pH 3 without HM). Kinetically, Cr(III)-muscovite provides a major pathway for Cr(VI) formation and Cr(VI) production rates may exceed those involving chromite depending on pH, available mineral surface areas in solution, and the abundance of Cr(III) present. However, when HM is introduced to the system, Cr(VI) production rates decrease by as much as 80%. This highlights that HM strongly decreases but may not completely suppress the formation and mobilization of Cr(VI). A Sri Lankan serpentine soil was utilized to provide context with regards to the experimental results. Despite Cr(VI) in the soil solids and Cr(VI) formation being favorable from Cr(III)-bearing minerals, no detectable Cr(VI) was released into soil solutions potentially due to the abundance of HM. Overall, the dynamic interactions of Cr(III)-bearing silicates and birnessite provide a kinetically favorable route of Cr(VI) formation which is tempered by humic matter.</P><P><B>Graphic Abstract</B> <IMG SRC='http://pubs.acs.org/appl/literatum/publisher/achs/journals/content/esthag/2013/esthag.2013.47.issue-17/es4015025/production/images/medium/es-2013-015025_0006.gif'></P><P><A href='http://pubs.acs.org/doi/suppl/10.1021/es4015025'>ACS Electronic Supporting Info</A></P>
DNA Methylation in Peripheral Blood: A Potential Biomarker for Cancer Molecular Epidemiology
Li, Lian,Choi, Ji-Yeob,Lee, Kyoung-Mu,Sung, Hyuna,Park, Sue K.,Oze, Isao,Pan, Kai-Feng,You, Wei-Cheng,Chen, Ying-Xuan,Fang, Jing-Yuan,Matsuo, Keitaro,Kim, Woo Ho,Yuasa, Yasuhito,Kang, Daehee Japan Epidemiological Association 2012 Journal of epidemiology Vol.22 No.5
<P>Aberrant DNA methylation is associated with cancer development and progression. There are several types of specimens from which DNA methylation pattern can be measured and evaluated as an indicator of disease status (from normal biological process to pathologic condition) and even of pharmacologic response to therapy. Blood-based specimens such as cell-free circulating nucleic acid and DNA extracted from leukocytes in peripheral blood may be a potential source of noninvasive cancer biomarkers. In this article, we describe the characteristics of blood-based DNA methylation from different biological sources, detection methods, and the factors affecting DNA methylation. We provide a comprehensive literature review of blood-based DNA methylation as a cancer biomarker and focus on the study of DNA methylation using peripheral blood leukocytes. Although DNA methylation patterns measured in peripheral blood have great potential to be useful and informative biomarkers of cancer risk and prognosis, large systematic and unbiased prospective studies that consider biological plausibility and data analysis issues will be needed in order to develop a clinically feasible blood-based assay.</P>
Kadowaki, Shigenori,Komori, Azusa,Takahari, Daisuke,Ura, Takashi,Ito, Seiji,Tajika, Masahiro,Niwa, Yasumasa,Oze, Isao,Muro, Kei Asian Pacific Journal of Cancer Prevention 2015 Asian Pacific journal of cancer prevention Vol.16 No.13
Background: Systemic chemotherapy for patients with metastatic gastric cancer (MGC) is generally palliative, although some patients experience long-term survival after treatment. Thus, we identified clinical characteristics that are associated with long-term survival of patients with MGC after palliative chemotherapy. Materials and Methods: We retrospectively reviewed 514 MGC patients who received systemic chemotherapy at our institution from 2001 to 2008. To identify clinical predictors of survival beyond 2 years, multivariate logistic regression analyses were performed, and 5-year survival rates were estimated among MGC patients following chemotherapy. Results: Among 514 patients, 96 (19%) and 16 (3%) survived beyond 2 and 5 years, respectively, and performance status of 0 or 1 (odds ratio [OR]=3.39; p=0.01), previous gastrectomy (OR=1.86; p=0.01), single metastatic site (OR=1.80; p=0.03), and normal alkaline phosphatase levels (OR=2.81; p<0.01) were identified as independent predictors of long-term survival. Of the 16 5-year survivors, six were alive at the end of the study and showed no evidence of disease despite cessation of chemotherapy. Conclusions: The present data demonstrate distinct clinical characteristics that are associated with long-term survival of MGC patients, and indicated that palliative chemotherapy can be curative in highly selected patients.